Cellectar Biosciences (NASDAQ:CLRB) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. CLRB has been the subject of several other reports. LADENBURG THALM/SH SH started coverage on Cellectar Biosciences in a research report on Thursday, […]
More Stories
Wells Fargo & Company Forecasts Strong Price Appreciation for Doximity (NASDAQ:DOCS) Stock
Doximity (NASDAQ:DOCS – Free Report) had its target price boosted by Wells Fargo & Company from $41.00 to $43.00 in...
Blueprint Medicines’ (BPMC) Outperform Rating Reiterated at Wedbush
Wedbush reaffirmed their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report report published...
Raymond James Lowers Nexus Industrial REIT (TSE:NXR.UN) Price Target to C$9.00
Nexus Industrial REIT (TSE:NXR.UN – Free Report) had its target price trimmed by Raymond James from C$9.75 to C$9.00 in...
TD Cowen Cuts Advanced Micro Devices (NASDAQ:AMD) Price Target to $150.00
Advanced Micro Devices (NASDAQ:AMD – Free Report) had its price target trimmed by TD Cowen from $185.00 to $150.00 in...
Choice Hotels International (NYSE:CHH) & Candlewood Hotel (OTCMKTS:CNDL) Critical Review
Choice Hotels International (NYSE:CHH – Get Free Report) and Candlewood Hotel (OTCMKTS:CNDL – Get Free Report) are both consumer discretionary...
Reviewing MYR Group (NASDAQ:MYRG) & SKK (NASDAQ:SKK)
SKK (NASDAQ:SKK – Get Free Report) and MYR Group (NASDAQ:MYRG – Get Free Report) are both construction companies, but which...